ACADIA Pharmaceuticals Inc. (ACAD)
$
20.06
Key metrics
Financial statements
Free cash flow per share
1.1148
Market cap
3.4 Billion
Price to sales ratio
3.3216
Debt to equity
0.0542
Current ratio
2.9106
Income quality
0.8458
Average inventory
24.5 Million
ROE
0.3067
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of small molecule drugs to address the unmet medical needs in central nervous system disorders. The company’s net income ratio is 0.24 reflecting its profitability margin. Despite the investment in research and development, the company reported selling, general, and administrative expenses of $488,428,000.00 indicating its operational overhead costs. The net total of other income and expenses is $27,281,000.00 reflecting non-core financial activities. Furthermore, the company incurred an income tax expense of $31,624,000.00 indicating its tax obligations. The income before tax ratio is 0.27 reflecting the pre-tax margin. ACADIA offers NUPLAZID (pimavanserin) for treating hallucinations and delusions associated with Parkinson's disease psychosis, while its pipeline includes pimavanserin, currently under phase 3 development for Alzheimer's disease psychosis and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for Rett syndrome; ACP-044, an innovative first-in-class orally administered non-opioid analgesic under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, undergoing phase 1 development for schizophrenia and cognitive dysfunction in Alzheimer's. Founded in 1993, ACADIA is headquartered in San Diego, California. Currently, the stock is affordable at $24.42 making it suitable for budget-conscious investors. Additionally, the stock has a high average trading volume of 2,049,093.00 indicating strong liquidity. With a mid-range market capitalization of $3,384,367,133.00 the company is regarded as a steady performer. ACADIA Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth in areas that address critical health challenges.
Is ACADIA Pharmaceuticals Inc. (ACAD) a good investment?
Investing in ACADIA Pharmaceuticals Inc. (ACAD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is ACADIA Pharmaceuticals Inc. (ACAD)'s stock forecast?
Analysts predict ACADIA Pharmaceuticals Inc. stock to fluctuate between $13.40 (low) and $26.65 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ACADIA Pharmaceuticals Inc.'s market capitalization?
As of 2025-10-13, ACADIA Pharmaceuticals Inc.'s market cap is $3,384,367,133, based on 168,712,220 outstanding shares.
How does ACADIA Pharmaceuticals Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., ACADIA Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ACADIA Pharmaceuticals Inc. (ACAD) stock?
To buy ACADIA Pharmaceuticals Inc. (ACAD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACAD. Place an order (Market, Limit, etc.).
What is the best time to invest in ACADIA Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did ACADIA Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $957,797,000 | EPS: $1.37 | Growth: -470.27%.
Where can I find ACADIA Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.acadia-pharm.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ACADIA Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for ACADIA Pharmaceuticals Inc. stock?
All-time high: $33.99 (2023-07-18) | All-time low: $12.24 (2022-06-21).
What are the key trends affecting ACADIA Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
seekingalpha.com
ACAD's thesis centers on Nuplazid and Daybue. These are two approved and cash-generating drugs that should help ACAD fund its CNS pipeline. ACAD's Q2 2025 revenues remain solid with Nuplazid and Daybue. Also, a near-term catalyst could be the EMA's decision for Daybue by Q1 2026. They also recently secured patent wins that should protect Nuplazid until 2030 and 2038, supporting durable cash flows.
prnewswire.com
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson's Disease and Movement Disorders® being held October 5-9, 2025, in Honolulu, Hawaii. The presentations highlight updates from the company's robust pipeline including preclinical efficacy, safety and mechanism of action findings on Acadia's investigational drug ACP-711, under deve.
zacks.com
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
investors.com
Shares of Acadia Pharmaceuticals toppled Wednesday after the biotech company's experimental treatment for a rare, genetic disorder failed.
reuters.com
Acadia Pharmaceuticals said on Wednesday that its experimental therapy to treat a rare metabolic condition failed to meet the main goal in a late-stage study.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported observational online, open-label, ongoing LOTUS study evaluating effectiveness and tolerability outcomes in patients with Rett syndrome who are prescribed DAYBUE® (trofinetide) under routine clinical care in the U.S. Findings included reported improvements in symptoms of Rett syndrome, with early.
seekingalpha.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Al Kildani - Corporate Participant Catherine E. Owen Adams - CEO & Director Elizabeth H.
See all news
